GSK Group (GSK) Company Overview – Stock Outlook, Earnings, Market Cap, Related Stocks & Headquarters Summary
GSK Group (GSK) stock, earnings, outlook, market cap, dividend, related stocks, and headquarters analysis. A global big-pharma leader focused on vaccines, HIV, respiratory, immunology, and oncology specialty medicines, with key variables being sales expansion of long-acting injectables in shingles, respiratory viruses, and HIV, along with stable shareholder returns, making it a representative healthcare stock.
🏢 What kind of company is GSK Group?
GSK is a UK-headquartered global diversified pharmaceutical company founded in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham. Following the spin-off of its Consumer Healthcare division, the company has shifted to a business structure focused on vaccines and specialty medicines, establishing itself as a core operator within the global big-pharma group.
It operates a diversified pharmaceutical portfolio spanning vaccines (shingles vaccine Shingrix, meningococcal, respiratory virus Arexvy, flu, pediatric vaccines), specialty medicines (long-acting injectable HIV treatments, dolutegravir-based regimens, respiratory, immunology, oncology, anti-infectives), and general medicines. It holds a leading global position in the vaccines and HIV therapeutic areas.
💰 How does GSK Group make money?
| Business Segment | Revenue Share | Description |
|---|---|---|
| Specialty Medicines | Core Growth Engine | HIV, respiratory, immunology, and oncology therapies |
| Vaccines | Mainstay | Shingles, meningococcal, respiratory virus, flu, and pediatric vaccines |
| General Medicines | Supplementary Business | Anti-infectives and other medicines |
Recent annual revenue has shown a resilient trend supported by double-digit growth in specialty medicines (HIV, respiratory, immunology, oncology) and steady contributions from the vaccines segment. The specialty medicines division has become the core growth engine of revenue, while newer vaccines such as Shingrix for shingles and Arexvy for respiratory virus are driving diversification of vaccine sales. Operating margin remains at a healthy level consistent with the big-pharma business model, with R&D pipeline depth and new-drug launch cadence serving as the key swing factors for margin trajectory.
📐 GSK Group market cap and company scale
Market capitalization stands at $104.3B with a workforce of 66,841명.
As a big-pharma diversified pharmaceutical company ranked among the top of the global healthcare sector by market cap, it is benchmarked against PFE, MRK, AZN, SNY, and NVS in vaccines and specialty medicines. Free cash flow is stable given the vaccine and HIV business profile, and its capital policy is characterized by a balance between R&D reinvestment, strategic M&A expansion, and steady shareholder returns since the spin-off of Consumer Healthcare.
📈 GSK Group outlook and share price trends
Diversification of the vaccine portfolio (shingles, respiratory virus, meningococcal, pediatric vaccines) and sales expansion of long-acting injectable HIV treatments serve as the core medium- to long-term growth engines. Pipeline expansion in oncology, immunology, and respiratory specialty medicines is also emerging as a new revenue pillar, alongside M&A-driven strengthening of the oncology and immunology segments. Short-term variables include US drug-pricing policy shifts, vaccine market competition (COVID, respiratory virus, flu), pipeline success/failure probabilities, and FX moves (British pound vs. US dollar), which can drive volatility.
- Vaccine portfolio diversification and expansion into newer vaccine markets
- Sales growth of long-acting injectable HIV treatments and specialty medicines
- R&D pipeline launches and M&A-driven expansion in oncology and immunology
⚔️ GSK Group core strengths and risks
Leading positions in the vaccines and HIV markets and stable free cash flow are strengths, while US drug-pricing policy and pipeline volatility are the key risks.
💪 Core Strengths
⚠️ Core Risks
🔄 GSK Group peers and related stocks (beneficiaries)
Direct competitors include global big-pharma peers PFE (Pfizer), MRK (Merck), AZN (AstraZeneca), SNY (Sanofi), and NVS (Novartis), which are commonly compared side by side. Within related names, BMY (Bristol-Myers Squibb) and LLY (Eli Lilly) sit adjacent on the oncology and biotech axis, while MRNA (Moderna) and NVAX (Novavax) sit adjacent on the vaccine axis. PFE, MRK, AZN, SNY, and NVS fall into the same big-pharma peer category, whereas BMY, LLY, MRNA, and NVAX branch off into the adjacent oncology and vaccine axis.
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
| PFE | Pfizer Inc | $24.91 | -0.9% | $142.0B | 19.1 | 1.6 | 8.29% | 6.91% |
| MRK | Merck & Co Inc | $129.79 | -0.4% | $320.6B | 36.5 | 7.0 | 18.97% | 2.52% |
| AZN | Astrazeneca plc | $171.34 | -1.1% | $265.7B | 25.6 | 5.3 | 21.99% | 1.94% |
| SNY | Sanofi ADR | $42.89 | -4.4% | $103.3B | 18.0 | 1.2 | 6.76% | 5.7% |
| NVS | Novartis AG ADR | $158.44 | -0.3% | $290.0B | 23.9 | 7.0 | 30.56% | 2.8% |
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Co | $64.86 | +2.8% | $132.4B | 18.2 | 6.6 | 38.84% | 3.89% |
| LLY | Lilly(Eli) & Co | $1154.97 | -4.5% | $1.09T | 41.6 | 34.9 | 107.64% | 0.6% |
 MRNA | Moderna Inc | $57.88 | +6.2% | $23.0B | - | 3.1 | -36.56% | - |
 NVAX | Novavax Inc | $7.44 | +1.4% | $1.2B | - | - | - | - |
✅ GSK Group investor checkpoints
Key checkpoints when investing in GSK. Vaccine portfolio expansion, sales growth of long-acting injectable HIV treatments, the R&D pipeline launch schedule, and US drug-pricing policy variables act as the key short- to medium-term drivers.
| Checkpoint | What to verify | Current status |
|---|---|---|
| 💉 Vaccine Sales | Shingles, respiratory virus, and meningococcal sales trends | Resilient growth trend |
| 🧬 HIV & Specialty | Long-acting injectable HIV and specialty-medicine growth | Double-digit growth maintained |
| 💰 Dividends & Capital Return | Dividend increases and buyback trends | Stable return pattern |
| 🏛️ Pricing Policy | US Medicare negotiations and drug-price cut impact | Requires monitoring |
US drug-price reduction policies and Medicare negotiations could affect short-term revenue and margin. Competition with PFE, MRK, AZN, SNY, and NVS in vaccines and specialty medicines, vaccine market competition with MRNA and NVAX, and FX swings also act as short-term revenue and margin volatility factors.
A global big-pharma diversified pharmaceutical company characterized by a diversified portfolio anchored in vaccines, HIV, and specialty medicines, alongside stable shareholder returns. Vaccine portfolio expansion, HIV sales growth, and the pipeline launch schedule are the key variables to monitor, and a dollar-cost-averaging approach with a long-term horizon is recommended.
이 글은 2026년 5월 21일 기준 정보입니다.